Immorta Bio, a longevity biotech company, announced new findings showing its SenoVax™ senolytic immunotherapy significantly boosts natural killer (NK) cell numbers and activity by clearing senescent cells. Covered under newly filed patent #63/789,097, this breakthrough may enhance the body’s ability to fight cancer and viral infections. Preclinical studies reveal SenoVax not only boosts immune response but may transfer cancer-fighting benefits between animals. Currently in development for lung cancer, SenoVax is designed to work alone or enhance existing therapies by removing the “senescent shield” protecting tumors.